학술논문

CD22low/Bcl-2high expression identifies poor response to inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia
Document Type
Correspondence
Source
In Blood Advances 24 January 2023 7(2):251-255
Subject
Clinical Trials and Observations
Lymphoid Neoplasia
Language
ISSN
2473-9529